Recent health news highlights include global bird flu restrictions impacting Brazilian chicken exports, advancements in ...

Caris Life Sciences shares ended trading at $28 per share on Wednesday, marking a 33% increase from its initial public offering (IPO) price of $21 per share.

Cancer-testing company raises $494 million in initial public offering.

Caris Life Sciences raised $494.1 million in its Nasdaq initial public offering, the cancer diagnostic firm said on Tuesday, ...

Caris plans to use the proceeds from its IPO to pay off about $400 million worth of debt, he noted, and it also intends to use the funds to drive toward profitability next year and continue expanding ...

The stock of Caris Life Sciences shined in its Nasdaq debut on Wednesday, pricing its heavily-subscribed initial public ...

The successful IPO of Caris Life Sciences makes its founder David Dean Halbert worth an estimated $3.3 billion.

Shares of Caris Life Sciences soared in their public debut Wednesday, as investors bought into the company’s business of ...

Caris Life Sciences shares rose on their first day of trading in their debut on Nasdaq. The biotechnology company started trading at $27 each on Wednesday afternoon, a day after the company's IPO was ...

Initial public offerings are like the ghosts in the 80s supernatural movie Poltergeist. They’re ba-ack! Caris Life Sciences, a company that uses artificial-intelligence technology to help develop ...

Live Updates Live Coverage Has Ended Today's IPO Receives Warm Welcome 12:53 pm by Gerelyn Terzo The markets rolled out the ...

Caris Life Sciences' shares jumped nearly 29% in their Nasdaq debut on Wednesday, fetching the cancer diagnostic firm a ...